Mylan’s Nod For US Advair Rival Puts It A Year Ahead Of The Pack

The FDA’s approval for Mylan’s Wixela Inhub generic rival to GSK’s Advair Diskus is likely to give the company around a year’s head-start on other US generics being developed by Sandoz and Hikma.